Sustained availability of 99mTc: Possible paths forward

Journal of Nuclear Medicine

Volumn 54, Issue 2, 2013, Pages 313-323

  Pillai, Maroor Raghavan Ambikalmajan ^a   Dash, Ashutosh ^a   Knapp, F F ^b  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

Accelerator production; Aqueous homogeneous reactor (AHR); Reactor production

Indexed keywords

2 BUTANONE; MOLYBDENUM 99; TECHNETIUM 99M; DIAGNOSTIC AGENT; MOLYBDENUM; RADIOISOTOPE; TECHNETIUM;

ARTICLE; ISOTOPE ANALYSIS; NEUTRON ACTIVATION ANALYSIS; NUCLEAR ENERGY; NUCLEAR POWER PLANT; NUCLEAR REACTOR; PRIORITY JOURNAL; REACTOR OPERATION; REACTOR OPTIMIZATION; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; CHEMISTRY; CYCLOTRON; INSTRUMENTATION; INTERNATIONAL COOPERATION; ISOTOPE LABELING; METHODOLOGY; NUCLEAR MEDICINE; RADIOACTIVITY; UNITED STATES;

CYCLOTRONS; INTERNATIONALITY; ISOTOPE LABELING; MOLYBDENUM; NUCLEAR MEDICINE; RADIOISOTOPES; RADIONUCLIDE GENERATORS; TECHNETIUM; UNITED STATES;

MLCS; MLOWN;

EID: 84873550668     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.110338     Document Type: Article

References (82)

1. Verbeek P. Report on Molybdenum-99 Production for Nuclear Medicine 2010-2020. State of the art. AIPES Report. November 2008. Available at: http://www.oecd-nea.org/med-radio/docs/200902-AIPESMolySupplyReport.pdf.
2. Technopolis Group. Radioisotopes in Medicine, Foresight of the Use of Reactor Isotopes until 2025. Technopolis Report. December 2008. Available at: http://www.technopolis-group.com/resources/downloads/life-sciences/ EN-Radioisotopes-in-Medicine-final.pdf.
3. Eckelman WC. Unparalleled contribution of technetium-99m to medicine over 5 decades. JACC Cardiovasc Imaging. 2009;2:364-368.
4. International Atomic Energy Agency. Technetium-99m Radiopharmaceuticals: Manufacture of Kits. Technical Report Series 466. 2008. Available at: http://www-pub.iaea.org/MTCD/publications/PubDetails.asp?pubId57867.
5. 99mTc: Radioisotopes Critical to Nuclear Medicine. 2009. Available at: http://www.lantheus.com/SupplyUpdate/pdf/Moly-FactSheet-v3-07Oct10.pdf.
6. International Atomic Energy Agency. IAEA Helps to Close Radioisotope Production Gap. Staff Report. 2011. Available at: http://www.iaea.org/ newscenter/news/2011/prodgap.html.
7. Bonet H, David B, Ponsard B. In: 9thInt. Topical Meeting on Research Reactor Fuel Management (RRFM). Hungary. 2005. Available at: http://www.euronuclaer. org/pdf/RRFM2005.Session1.pdf.
8. Von Hippel FN, Kahn LH. Feasibility of eliminating the use of highly enriched uranium in the production of medical isotopes. Sci Global Security. 2006;14:151-162.
9. Department of Homeland Security Nuclear Assessment Program. Nuclear Smuggling. Available at: www.exportcontrol.org/library/conferences/1379/005- Proliferation-Threat-Brief-Nuclear-Smuggling-Zachary-K.pdf.
10. Loukianova A, Hansell C. Leveraging US policy for a global commitment to HEU elimination. Nonproliferation Rev. 2008;15:159-183.
11. Hansell C. Nuclear medicine's double hazard imperiled treatment and the risk of terrorism. Nonproliferation Rev. 2008;15:185-208.
12. U.S. National Nuclear Security Administration. Office of Global Threat Reduction. Available at: http://www.nnsa.energy.gov/mediaroom/pressreleases/ mo99noheu61512.
13. Summary of Section 630, Medical isotope production, under Title VI, Nuclear Matters, Subtitle B, General Nuclear Matters. Available at: www.ne.doe.gov/energypolicyact2a.html.
14. Committee on Medical Isotope Production Without Highly Enriched Uranium, National Research Council. Medical Isotope Production Without the Use of Highly Enriched Uranium. January 2009. Available at: http://www.nap.edu/catalog.php? record-id512569#description.
15. Remarks by President Barack Obama. White House website. Available at: http://www.whitehouse.gov/the-press-office/Remarks-By-President-Barack-Obama-In- Prague-As-Delivered. April 5, 2009.
16. Participating States. Work Plan of the Washington Nuclear Security Summit, Statements and Releases from the Washington Nuclear Security Summit. Washington, D.C., April 12-13, 2010. Available at: http://www.whitehouse.gov/ thepress-office/work-plan-washington-nuclear-security-summit.
17. US House of Representatives Subcommittee on Energy and Environment. American Medical Isotopes Production Act of 2009, Section by Section Summary. Available at: http://energycommerce.house.gov/Press-111/20090908/hr3276-% 20sectionbysection.pdf.
18. American Medical Isotopes Production Act of 2011. Civic Impulse. Available at: http://www.govtrack.us/congress/billtext.xpd?bill5s112-99.
19. Vandegrift GF. Mo-99 production. In: Progress in Chemical Processing of LEU Targets for Mo-99 Production - 1997. Proceedings of 1997 International Meeting on Reduced Enrichment for Research and Test Reactors. Jackson Hole, WY, Oct. 1997. Lemont, IL: Argonne National Laboratory; 2009.
20. 99Mo production from high- to low-enriched uranium. Ind Eng Chem Res. 2000;39:3140-3145.
21. McDonald MJ, Carson SD, Naranjo GE, et al. Challenges of extracting and purifying fission-produced molybdenum-99. Ind Eng Chem Res. 2000;39: 3146-3150.
22. 99Mo production with HEU and LEU targets. International Meeting on Reduced Enrichment for Research and Test Reactors, RERTR Meeting 2005. Available at: http://www.rertr.anl.gov/ RERTR27/Abstracts/S8-1-VandeGrift.html.
23. 99Mo produced with LEU. International Panel on Fissile Materials; Aug. 25, 2010. Available at: http://www.fissilematerials.org/blog/2010/08/south-african-company-del.html.
24. International Atomic Energy Agency. CRP on Production of Mo-99 from LEU or Neutron Activation. Available at: www.iaea.org/OurWork/ST/NE/NEFW/nfcms- researchreactors-Mo99.html.
25. International Atomic Energy Agency. Homogeneous Aqueous Solution Nuclear Reactors for the Production of Mo-99 and Other Short Lived Radioisotopes. IAEA TECDOC Report 1601. Vienna, Austria: IAEA; September 2008.
26. Parma EJ, Coats RL, Dahl JJ. Sandia National Laboratories Medical Isotope Reactor Concept. Report SAND 2010-1816. Albuquerque, NM: SAND; 2010.
27. Taylor RF, Sharratt EW, de Chazal LEM, et al. Dissolution rates of uranium dioxide sintered pellets in nitric acid systems. J Appl Chem. 1963;13:32-40.
28. Shabbir M, Robins RG. Kinetics of the dissolution of uranium dioxide in nitric acid I. J App Chem. 1968;18:129-134.
29. 2. J Nucl Sci Technol. 1995;32:157-159.
30. 2 powders in nitric acid. J Nucl Mater. 1995;224:266-272.
31. Pillai MRA, Knapp FF Jr. Overcoming the Tc-99m shortage: are options being overlooked? J Nucl Med. 2011;52:15N-16N, 28N.
32. Pillai MRA, Knapp FF Jr. Molybdenum-99 production from reactor irradiation of molybdenum targets, a viable strategy for enhanced availability of technetium-99m. Q J Nucl Med Mol Imaging. In press.
33. International Atomic Energy Agency. Operation Research Reactors in the World [database]. Available at: www.naweb.iaea.org/napc/physics/research- reactors/database/RR%20Data%20Base/datasets/foreword-home.html.
34. GE Hitachi Nuclear Energy to deliver life-saving medical isotope molybdenum-99 using alternative to highly enriched uranium. Press release, GE-Hitachi, 25 January 2010. Available at: www.ge-energy.com/about/press/en/ 2010-press/012510.htm.
35. Forrest W. GE Hitachi puts molybdenum-99 project on ice. http://www.auntminnie.com/index.aspx?sec5sup- n&sub5mol&pag5dis&ItemID598224.
36. 99Mo based on solvent extraction and column chromatography. Appl Radiat Isot. 2012;68:1-4.
37. Khlopin Radium Institute. Research and production section for radiopharmaceuticals fabrication on the basis of reactor nuclide. Available at: http://www.khlopin. ru/english/radiopharm-fabricating.php.
38. 99mTc solvent extraction system. Available at: http://www.rcrusia.com.ar/espanol/cooperacion/pub4.pdf.
39. 99mTc generator concept. J Radioanal Nucl Chem Lett. 1987;119:315-325.
40. 99mTc into MEK from large quantity of molybdate retained on alumina column. J Radioanal Nucl Chem. 1990;145:311-320.
41. 99Mo of low/medium specific activity based on solid phase column extraction technique: suitability for use in diagnostic radiopharmaceuticals. J Nucl Med. 2009;509(suppl 2):397P.
42. 99Mo using a tiny Dowex-1 column in tandem with a small alumina column. Appl Radiat Isot. 2008;66:1814-1817.
43. Christian JD, Petti DA, Kirkham RJ, Bennett RG. Advances in sublimation separation of technetium from low-specific-activity molybdenum-99. Ind Eng Chem Res. 2000;39:3157-3168.
44. 99mTc isotope generator: SUBLITECH. J Radioanal Nucl Chem. 1988;28:71-79.
45. 99mTc for nuclear medicine. Appl Radiat Isot. 1997;48:1027-1033.
46. 99mTc Generators. Report IAEA-TECDOC-852, Vienna, 1995. Available at http://www-pub. iaea.org/MTCD/publications/PDF/te-852-prn.pdf.
47. Knapp FF Jr, Beets AL, Guhlke S, et al. Development of the alumina-based tungsten-188/rhenium-188 generator and use of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res. 1997;17:1783-1795.
48. 99mTc generator: a simple and convenient method for concentrating generator eluate for clinical use. Nucl Med Commun. 1993;14:995-997.
49. 99Mo. Appl Radiat Isot. 1997; 48:607-611.
50. 188Re nuclide pair separation. Sep Sci Technol. 2009;44:1074-1098.
51. 99mTc generator column. In: Proceedings of 2007 AIChE Annual Meeting, Nov. 4-9, 2007, Salt Lake City, Utah. Available at: http://aiche. confex.com/aiche/2007/preliminaryprogram/abstract- 93290.htm.
52. Lee JS, Han HS, Park UJ, Son KJ, Shin HY, Hong SB, Jang KD Lee JS, inventors; Korea Atomic Energy Research Institute, assignee. Adsorbents for Radioisotopes, Preparation Method Thereof, and Radioisotope Generators Using the Same. US patent 2009/027788 A1. November 12, 2009.
53. 99mTc generator. J Nanosci Nanotechnol. 2008;8:4447-4452.
54. 99mTc generator for biomedical applications. Chromatographia. 2010;72:875-884.
55. 188Re generator technology. Anal Chem. 2011;83:6342-6348.
56. 99Mo and nanocrystalline g-Al2O3 as column matrix. Nucl Med Biol. In press.
57. 90Y suitable for targeted therapy. Nucl Med Biol. 2008;35:245-253.
58. 188Re electrochemical generator with potential for medical applications. Radiochimica Acta. 2009;97:309-317.
59. Chakravarty R, Dash A, Pillai MRA. Electrochemical separation is an attractive strategy for development of radionuclide generators for medical applications. Curr Radiopharm. 2012;5:271-287.
60. 99Mo. Nucl Med Biol. 2010;37: 21-28.
61. International Atomic Energy Agency. Annual Report 2009. 2009:55. Available at: www.iaea.org/Publications/Reports/Anrep2009/anrep2009-full.pdf.
62. Ruth T. Accelerating production of medical isotopes. Nature. 2009;457:536-537.
63. Freeman T. Medical isotope supplies: a game plan for the future. Editorial. Medical Physics website. December 8, 2008. Available at: http://medicalphysicsweb. org/cws/article/opinion/36974.
64. Fong A, Meyer TI, Zala K. Making Medical Isotopes, Report of the Task Force on Alternatives for Medical isotope Production. Vancouver, Canada: TRIUMF; 2008. Available at: www.triumf.ca/report-medical-isotope-production.
65. Committee on Medical Isotope Production Without Highly Enriched Uranium. Medical Isotope Production Without Highly Enriched Uranium. Report 14. January 2009. Washington, DC: National Academy of Sciences; 2009.
66. Securing a Supply of Critical Medical Isotopes for Canada Using ZEUM Technology, an Expression of Interest Submitted to the Expert Review Panel on Medical-Isotope Production. July 31, 2009. Available at: http://www.triumf.ca/ sites/default/files/ZEUM-Panel-Submission-vFINAL.pdf.
67. NNSA Signs Cooperative Agreement to Produce Molybdenum-99 in the United States Without the Use of Highly Enriched Uranium. Press release. November 1, 2011. Available at: http://nnsa.energy.gov/mediaroom/pressreleases/ norhtstarmo99.
68. 99mTc on a medical cyclotron: a feasibility study. J Nucl Med. 1971;12:739-741.
69. 99mTc with proton beams and enriched 100 Mo targets. In: Production Technologies for Molybdenum-99 and Technetium-99m. IAEA-TECDOC-1065. Vienna, Austria: International Atomic Energy Agency; 1999:87-112.
70. 99mTc generators. Int J Rad Appl Instrum A. 1991;42:643-657.
71. 99Mo. Appl Radiat Isot. 1999;51:69-80.
72. 99Mo. J Radioanal Nucl Chem. 2003;257:195-201.
73. Targholizadeh H, Raisali G, Jalilian AR, et al. Cyclotron production of technetium radionuclides using a natural metallic molybdenum thick target and consequent preparation of [Tc]-BRIDA as a radio-labelled kit sample. Nukleonika. 2010;55:113-118.
74. Takacs S, Tarkanyi F, Sonck M, Hermanne A. Investigation of the natMo(p, xn)96mgTc nuclear reaction to monitor proton beam: new measurements and consequences on the earlier reported data. Nucl Instrum Methods Phys Res B. 2002;198:183-196.
75. 99mTc: an approach to the medical isotope crisis. J Nucl Med. 2010;51:13N-16N.
76. International Atomic Energy Agency. Directory of Cyclotrons Used for Radionuclide Production in Member States: 2006 Update. Report IAEA-DCRP/2006. Vienna, Austria: IAEA; 2006. Available at: www-naweb.iaea.org/napc/iachem/ cyclotrons/PDF/DCRP.pdf.
77. 99mTcO4 -. Nucl Med Biol. 2012;39:551-559.
78. Abderrahim HA, Baeten P, Bruyn DD, et al. MYRRHA, a multipurpose hybrid research reactor for high-end applications. Nucl Phys News. 2010;20:24-28.
79. Piefer GR, Pitas KM, Van Abel EN, et al. Mo-99 production using a subcritical assembly. In: 1st Annual Molybdenum-99 Topical Meeting (Mo-99 2011), Dec. 4-7, 2011. Available at: theltemes.net/cv/publications/nonreviewed/.
80. Clark BE. Financial support, backing from leaders helped Janesville win $85 million factory. Available at: http://www.wisbusiness.com/index.iml? Article5 264341.
81. Hillman BJ, Frank RA, Rodriguez GM. New pathways to Medicare coverage for Innovative PET radiopharmaceuticals: report of a Medical Imaging & Technology Alliance (MITA) Workshop. J Nucl Med. 2012;53:336-342.
82. Seeverens HJJ. The economics of the molybdenum-99/technetium-99m supply chain. Dutch J Nucl Med. 2010;32:604-608.